Richard Platt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Richard Platt has a total of 204 co-authors. Here are the top co-authors by number of shared publications:
- Adrian F. Hernandez
Duke University School of Medicine, Durham, North Carolina, USA
6 shared publications - Jeffrey Brown
TriNetX, Cambridge, USA
5 shared publications - Ken Kleinman
Department of Biostatistics, School of Public Health and Human Sciences, University of Massachusetts Amherst, Amherst, MA, USA
5 shared publications - Susan S. Huang
University of California Irvine School of Medicine
5 shared publications - Edward Septimus
Department of Internal Medicine, Texas A&M Health Science Center, USA
4 shared publications Andrew L. Miner
Department of Ambulatory Care and Prevention, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
3 shared publications
Latest Publications
- Open Access
- 13 September 2023
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 45 (2) , 237-240
Assessing past versus present severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection: A survey of criteria for discontinuing precautions in asymptomatic patients testing positive on admission
Infection prevention program leaders report frequent use of criteria to distinguish recently recovered coronavirus disease 2019 (COVID-19) cases from actively infectious cases when incidentally positive asymptomatic patients were identified on routine severe acute respiratory coronavirus virus 2 (SARS-CoV-2) polymerase chain reaction (PCR) testing. Guidance on appropriate interpretation of high-sensitivity molecular tests can prevent harm from unnecessary precautions that delay admission and impede medical care.
- 13 September 2023
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 45 (2) , 237-240
Open AccessAssessing past versus present severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection: A survey of criteria for discontinuing precautions in asymptomatic patients testing positive on admission
Infection prevention program leaders report frequent use of criteria to distinguish recently recovered coronavirus disease 2019 (COVID-19) cases from actively infectious cases when incidentally positive asymptomatic patients were identified on routine severe acute respiratory coronavirus virus 2 (SARS-CoV-2) polymerase chain reaction (PCR) testing. Guidance on appropriate interpretation of high-sensitivity molecular tests can prevent harm from unnecessary precautions that delay admission and impede medical care.
- Open Access
- 1 June 2023
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 44 (12) , 2074-2077
Coronavirus disease 2019 (COVID-19) infection prevention practices that exceed Centers for Disease Control and Prevention (CDC) guidance: Balancing extra caution against impediments to care
In a survey of infection prevention programs, leaders reported frequent clinical and infection prevention practice modifications to avoid coronavirus disease 2019 (COVID-19) exposure that exceeded national guidance. Future pandemic responses should emphasize balanced approaches to precautions, prioritize educational campaigns to manage safety concerns, and generate an evidence-base that can guide appropriate infection prevention practices.
- 1 June 2023
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 44 (12) , 2074-2077
Open AccessCoronavirus disease 2019 (COVID-19) infection prevention practices that exceed Centers for Disease Control and Prevention (CDC) guidance: Balancing extra caution against impediments to care
In a survey of infection prevention programs, leaders reported frequent clinical and infection prevention practice modifications to avoid coronavirus disease 2019 (COVID-19) exposure that exceeded national guidance. Future pandemic responses should emphasize balanced approaches to precautions, prioritize educational campaigns to manage safety concerns, and generate an evidence-base that can guide appropriate infection prevention practices.
- 1 July 2021
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 385 (1) , 5-7
Is Learning Worth the Trouble? — Improving Health Care System Participation in Embedded Research
To help address important health issues, embedded pragmatic clinical trials could generate real-world evidence without the limitations associated with observational studies or the time, expense, and lack of generalizability associated with conventional clinical trials.
- 1 July 2021
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 385 (1) , 5-7
Is Learning Worth the Trouble? — Improving Health Care System Participation in Embedded Research
To help address important health issues, embedded pragmatic clinical trials could generate real-world evidence without the limitations associated with observational studies or the time, expense, and lack of generalizability associated with conventional clinical trials.
- Top Cited Papers
- 1 January 2021
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 129, 60-67
PCORnet® 2020: current state, accomplishments, and future directions
- 1 January 2021
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 129, 60-67
Top Cited PapersPCORnet® 2020: current state, accomplishments, and future directions
- Open Access
Characteristics of 24,516 Patients Diagnosed with COVID-19 Illness in a National Clinical Research Network: Results from PCORnet ®
Background: National data from diverse institutions across the United States are critical for guiding policymakers as well as clinical and public health leaders. This study characterized a large national cohort of patients diagnosed with COVID-19 in the U.S., compared to patients diagnosed with viral pneumonia and influenza. Methods and Findings: We captured cross-sectional information from 36 large healthcare systems in 29 U.S. states, participating in PCORnet ® , the National Patient-Centered Clinical Research Network. Patients included were those diagnosed with COVID-19, viral pneumonia and influenza in any care setting, starting from January 1, 2020. Using distributed queries executed at each participating institution, we acquired information for patients on care setting (any, ambulatory, inpatient or emergency department, mechanical ventilator), age, sex, race, state, comorbidities (assessed with diagnostic codes), and medications used for treatment of COVID-19 (hydroxychloroquine with or without azithromycin; corticosteroids, anti-interleukin-6 agents). During this time period, 24,516 patients were diagnosed with COVID-19, with 42% in an emergency department or inpatient hospital setting; 79,639 were diagnosed with viral pneumonia (53% inpatient/ED) and 163,984 with influenza (41% inpatient/ED). Among COVID-19 patients, 68% were 20 to <65 years of age, with more of the hospitalized/ED patients in older age ranges (23% 65+ years vs. 12% for COVID-19 patients in the ambulatory setting). Patients with viral pneumonia were of a similar age, and patients with influenza were much younger. Comorbidities were common, especially for patients with COVID-19 and viral pneumonia, with hypertension (32% for COVID-19 and 46% for viral pneumonia), arrhythmias (20% and 35%), and pulmonary disease (19% and 40%) the most common. Hydroxychloroquine was used in treatment for 33% and tocilizumab for 11% of COVID-19 patients on mechanical ventilators (25% received azithromycin as well). Conclusion and Relevance: PCORnet leverages existing data to capture information on one of the largest U.S. cohorts to date of patients diagnosed with COVID-19 compared to patients diagnosed with viral pneumonia and influenza.
Open AccessCharacteristics of 24,516 Patients Diagnosed with COVID-19 Illness in a National Clinical Research Network: Results from PCORnet ®
Background: National data from diverse institutions across the United States are critical for guiding policymakers as well as clinical and public health leaders. This study characterized a large national cohort of patients diagnosed with COVID-19 in the U.S., compared to patients diagnosed with viral pneumonia and influenza. Methods and Findings: We captured cross-sectional information from 36 large healthcare systems in 29 U.S. states, participating in PCORnet ® , the National Patient-Centered Clinical Research Network. Patients included were those diagnosed with COVID-19, viral pneumonia and influenza in any care setting, starting from January 1, 2020. Using distributed queries executed at each participating institution, we acquired information for patients on care setting (any, ambulatory, inpatient or emergency department, mechanical ventilator), age, sex, race, state, comorbidities (assessed with diagnostic codes), and medications used for treatment of COVID-19 (hydroxychloroquine with or without azithromycin; corticosteroids, anti-interleukin-6 agents). During this time period, 24,516 patients were diagnosed with COVID-19, with 42% in an emergency department or inpatient hospital setting; 79,639 were diagnosed with viral pneumonia (53% inpatient/ED) and 163,984 with influenza (41% inpatient/ED). Among COVID-19 patients, 68% were 20 to <65 years of age, with more of the hospitalized/ED patients in older age ranges (23% 65+ years vs. 12% for COVID-19 patients in the ambulatory setting). Patients with viral pneumonia were of a similar age, and patients with influenza were much younger. Comorbidities were common, especially for patients with COVID-19 and viral pneumonia, with hypertension (32% for COVID-19 and 46% for viral pneumonia), arrhythmias (20% and 35%), and pulmonary disease (19% and 40%) the most common. Hydroxychloroquine was used in treatment for 33% and tocilizumab for 11% of COVID-19 patients on mechanical ventilators (25% received azithromycin as well). Conclusion and Relevance: PCORnet leverages existing data to capture information on one of the largest U.S. cohorts to date of patients diagnosed with COVID-19 compared to patients diagnosed with viral pneumonia and influenza.
- Open Access
- 1 March 2020
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 17, 100515
Considerations for using distributed research networks to conduct aspects of randomized trials
- 1 March 2020
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 17, 100515
Open AccessConsiderations for using distributed research networks to conduct aspects of randomized trials
- 20 October 2019
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 107 (4) , 966-977
Reproducing Protocol‐Based Studies Using Parameterizable Tools—Comparison of Analytic Approaches Used by Two Medical Product Surveillance Networks
The US Sentinel System and the Canadian Network for Observational Drug Effect Studies (CNODES) are two medical product safety surveillance networks. Using Sentinel's preprogrammed, parameterizable analytic tools, we reproduced two protocol‐based studies conducted by CNODES to assess the risks of acute pancreatitis and heart failure (HF) associated with the use of incretin‐based drugs, compared with use of ≥ 2 oral hypoglycemic agents. Results from the replication new‐user cohort analyses aligned with those from the CNODES nested case‐control studies. The adjusted hazard ratios were 0.95 (0.81–1.12; vs. 1.03 (0.87–1.22) in CNODES) for acute pancreatitis and 0.91 (0.84–1.00; vs. 0.82 (0.67–1.00) in CNODES) for HF among patients without HF history. The CNODES's common protocol approach allows studies tailored to specific safety questions, whereas the Sentinel's common data model plus pretested program approach enables more rapid analysis. Despite these differences, it is possible to obtain comparable results using both approaches.
- 20 October 2019
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 107 (4) , 966-977
Reproducing Protocol‐Based Studies Using Parameterizable Tools—Comparison of Analytic Approaches Used by Two Medical Product Surveillance Networks
The US Sentinel System and the Canadian Network for Observational Drug Effect Studies (CNODES) are two medical product safety surveillance networks. Using Sentinel's preprogrammed, parameterizable analytic tools, we reproduced two protocol‐based studies conducted by CNODES to assess the risks of acute pancreatitis and heart failure (HF) associated with the use of incretin‐based drugs, compared with use of ≥ 2 oral hypoglycemic agents. Results from the replication new‐user cohort analyses aligned with those from the CNODES nested case‐control studies. The adjusted hazard ratios were 0.95 (0.81–1.12; vs. 1.03 (0.87–1.22) in CNODES) for acute pancreatitis and 0.91 (0.84–1.00; vs. 0.82 (0.67–1.00) in CNODES) for HF among patients without HF history. The CNODES's common protocol approach allows studies tailored to specific safety questions, whereas the Sentinel's common data model plus pretested program approach enables more rapid analysis. Despite these differences, it is possible to obtain comparable results using both approaches.
- Open Access
- 5 April 2019
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 2 (4) , e192200
The Emergence of Population Health in US Academic Medicine
Much attention has been focused in recent years on improving population health. This emphasis marks an acknowledgment that the poor performance of the United States on many indicators of health has persisted despite US leadership in many aspects of health care delivery and that other factors, like social determinants of health, must receive greater attention if national health goals and health care cost-savings goals are to be achieved.1 Further, improving population health aligns with language introduced through the triple-aim framework2 and the accompanying shift toward a value-based health care paradigm, in which accountable care and accountable health communities figure prominently. Finally, the focus on population health reflects advances in addressing root causes of health and disease and in identifying and testing sector- and discipline-bridging approaches to health promotion and disease prevention to improve health and health equity.
- 5 April 2019
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 2 (4) , e192200
Open AccessThe Emergence of Population Health in US Academic Medicine
Much attention has been focused in recent years on improving population health. This emphasis marks an acknowledgment that the poor performance of the United States on many indicators of health has persisted despite US leadership in many aspects of health care delivery and that other factors, like social determinants of health, must receive greater attention if national health goals and health care cost-savings goals are to be achieved.1 Further, improving population health aligns with language introduced through the triple-aim framework2 and the accompanying shift toward a value-based health care paradigm, in which accountable care and accountable health communities figure prominently. Finally, the focus on population health reflects advances in addressing root causes of health and disease and in identifying and testing sector- and discipline-bridging approaches to health promotion and disease prevention to improve health and health equity.
- 15 January 2019
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 29 (S1) , 3-7
How pharmacoepidemiology networks can manage distributed analyses to improve replicability and transparency and minimize bias
Several pharmacoepidemiology networks have been developed over the past decade that use a distributed approach, implementing the same analysis at multiple data sites, to preserve privacy and minimize data sharing. Distributed networks are efficient, by interrogating data on very large populations. The structure of these networks can also be leveraged to improve replicability, increase transparency, and reduce bias. We describe some features of distributed networks using, as examples, the Canadian Network for Observational Drug Effect Studies, the Sentinel System in the USA, and the European Research Network of Pharmacovigilance and Pharmacoepidemiology. Common protocols, analysis plans, and data models, with policies on amendments and protocol violations, are key features. These tools ensure that studies can be audited and repeated as necessary. Blinding and strict conflict of interest policies reduce the potential for bias in analyses and interpretation. These developments should improve the timeliness and accuracy of information used to support both clinical and regulatory decisions.
- 15 January 2019
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 29 (S1) , 3-7
How pharmacoepidemiology networks can manage distributed analyses to improve replicability and transparency and minimize bias
Several pharmacoepidemiology networks have been developed over the past decade that use a distributed approach, implementing the same analysis at multiple data sites, to preserve privacy and minimize data sharing. Distributed networks are efficient, by interrogating data on very large populations. The structure of these networks can also be leveraged to improve replicability, increase transparency, and reduce bias. We describe some features of distributed networks using, as examples, the Canadian Network for Observational Drug Effect Studies, the Sentinel System in the USA, and the European Research Network of Pharmacovigilance and Pharmacoepidemiology. Common protocols, analysis plans, and data models, with policies on amendments and protocol violations, are key features. These tools ensure that studies can be audited and repeated as necessary. Blinding and strict conflict of interest policies reduce the potential for bias in analyses and interpretation. These developments should improve the timeliness and accuracy of information used to support both clinical and regulatory decisions.
- 3 January 2019
- Published by The Duke Clinical Research Institute
FAQ